> > > 【スタッフ紹介】遠西 大輔

【スタッフ紹介】遠西 大輔

【卒業年】 2002年(平成14年)

【学位取得年月】 2011年(平成23年)3月

【専門領域】 血液腫瘍学,遺伝子腫瘍学

【資格】
総合内科専門医(日本内科学会),血液専門医,指導医(日本血液学会),がん薬物療法専門医(日本臨床腫瘍学会)

【略歴】
2002年(平成14年) 3月 岡山大学医学部医学科卒業
2002年(平成14年) 6月 呉共済病院内科研修医
2004年(平成16年) 6月 岡山医療センター 血液・腫瘍内科 レジデント
2005年(平成17年) 4月 癌研有明病院 化学療法科 レジデント
2007年(平成19年) 6月 岡山大学医学部・歯学部附属病院 血液・腫瘍内科 医員
2008年(平成20年) 4月 岡山大学大学院医歯薬学総合研究科 病態制御科学 入学
2011年(平成23年) 3月 岡山大学大学院医歯薬学総合研究科 病態制御科学 修了
2011年(平成23年) 5月 Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada, Post-doctoral fellow
2018年(平成30年) 4月 岡山大学病院 血液・腫瘍内科 助教
2019年(令和元年) 11月 岡山大学病院 ゲノム医療総合推進センター 血液・腫瘍内科 准教授

【賞罰】
2011年(平成23年) 岡山医学会賞 総合研究奨励賞(山田賞)
2011年(平成23年) 日本学術振興会:海外特別研究員
2011年(平成23年) 日本学術振興会:特別研究員
2011年(平成23年) かなえ海外留学助成
2011年(平成23年) 先進医薬海外留学助成
2013年(平成25年) 上原記念財団海外留学助成
2013年(平成25年) Banting Postdoctoral Fellowship, The Canadian Institutes of Health Research (CIHR)
2013年(平成25年) Post-doctoral fellowship, Michael-Smith Foundation, Canada
2014-2017年(平成26−29年) American Hematology Society Abstract Achievement Awards

【一言】
患者さんやその御家族の気持ちを考えながら医療を提供したいと思っております。

がん遺伝子解析に基づく個別化治療によって、多くの患者さんがその恩恵に預かれるよう、研究、教育に従事して参ります。

【研究テーマ】悪性リンパ腫の分子病態の解明と新規治療の開発

【主な業績】
最近の業績(Pubmedへのリンク)

Ennishi D, Healy S, Bashashati A, Saberi SA, Hother C, Mottok A, Chan FC, Chong L, Kridel R, Boyle1 M, Meissner B, Aoki T, Takata K, Woolcock BW, Viganò E, Abraham L, Gold M, Molday LL, Molday RS, Telenius A, Li MY, Wretham N, Santos ND, Wong M, Viller NN, Uger RA, Duns G, Baticados A, Madero A, Farinha P, Slack GW, Susana Ben-Neriah, Lai D, Zhang AW, Salehi S, Shulha HP, Chiu DS, Mostafavi S, Gerrie AS, Huang DW, Rushton C, Villa D, Sehn LH, Savage KJ, Mungal AJ, Weng AP, Bally MB, Morin RD,Cohen Freue GV, Staudt LM, Connors JM, Marra MA, Shah SP, Gascoyne RD, Scott DW and Steidl C. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature Med. 2020 Feb 24, epub.

Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discovery. 2019 April 1 2019 9 (4) 546-563

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019 Jan 20;37(3):190-201

Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nature Communications. 2018 Oct 1;9(1):4001

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018 May 3;131(18)

Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nature Communications. 2018 Jan 15;9(1):222

Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017 May 18;129(20):2760-2770.

Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery. 2017 Jan;7(1):38-53

Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG. Tumor suppression and therapeutic restoration of HVEM (TNFSRF14) in lymphoma. Cell. 2016 Oct 6;167(2):405-418

Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016 May 5;127(18):2182-8.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncology. 2015 Sep;16(9):1111-1122

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, Lee JE, Chen HT, Ennishi D, Scott DW, Mottok A, Hother C, Liu S, Cao XJ, Tam W, Shaknovich R, Garcia BA, Gascoyne RD, Ge K, Shilatifard A, Elemento O, Nussenzweig A, Melnick AM, Wendel HG. The histone lysine methyltransferase KMT2D sustains a gene expression progr m that represses B cell lymphoma development. Nature Medicine. 2015 Oct;21(10):1199-208

Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM, Scott DW, Gascoyne RD. Cell of origin of transformed follicular lymphoma. Blood. 2015 Oct 29;126(18):2118-27

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin Embedded Tissue Biopsies. J Clin Oncol. 2015 Sep 10;33(26):2848-56

Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, Kagami Y, Sunami K, Yamane H, Nishikori M, Kosugi H, Yujiri T, Hyo R, Katayama N, Kinoshita T, Nakamura S. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011 Jul;22(7):1601-7.

Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010 Dec 9;116(24):5119-25.

Ennishi D, Asai H, Maeda Y, Shinagawa K, Ikeda K, Yokoyama M, Terui Y, Takeuchi K, Yoshino T, Matsuo K, Hatake K, Tanimoto M. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2010 Jun;21(6):1217-21.

Ennishi D, Maeda Y, Niiya M, Shinagawa K, Tanimoto M. Incidental detection of acute lymphoblastic leukemia on [18F] fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2009 Dec 20;27(36):e269-70

Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res. 2009 May 15;15(10):3624-32

Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M, Hatake K. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol. 2009 Mar;20(3):526-33.

Ennishi D, Yokoyama M, Terui Y, Takeuchi K, Ikeda K, Tanimoto M, Hatake K. Does rituximab really induce hepatitis C virus reactivation? J Clin Oncol. 2008 Oct 1;26(28):4695-6

Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M, Hatake K. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008 Nov;19(11):1921-6

戻る